MBX BIOSCIENCES INC (MBX) Stock Fundamental Analysis

NASDAQ:MBX • US55287L1017

36.55 USD
-0.18 (-0.49%)
Last: Feb 25, 2026, 11:19 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall MBX gets a fundamental rating of 3 out of 10. We evaluated MBX against 192 industry peers in the Pharmaceuticals industry. While MBX has a great health rating, there are worries on its profitability. MBX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • MBX had negative earnings in the past year.
  • MBX had a negative operating cash flow in the past year.
MBX Yearly Net Income VS EBIT VS OCF VS FCFMBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • MBX has a better Return On Assets (-20.12%) than 60.94% of its industry peers.
  • MBX's Return On Equity of -20.77% is fine compared to the rest of the industry. MBX outperforms 68.23% of its industry peers.
Industry RankSector Rank
ROA -20.12%
ROE -20.77%
ROIC N/A
ROA(3y)-39.9%
ROA(5y)N/A
ROE(3y)-42.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBX Yearly ROA, ROE, ROICMBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60

1.3 Margins

  • MBX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBX Yearly Profit, Operating, Gross MarginsMBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for MBX has been increased compared to 1 year ago.
  • MBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MBX Yearly Shares OutstandingMBX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
MBX Yearly Total Debt VS Total AssetsMBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 78.62 indicates that MBX is not in any danger for bankruptcy at the moment.
  • MBX has a Altman-Z score of 78.62. This is amongst the best in the industry. MBX outperforms 97.92% of its industry peers.
  • MBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 78.62
ROIC/WACCN/A
WACCN/A
MBX Yearly LT Debt VS Equity VS FCFMBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • MBX has a Current Ratio of 32.95. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
  • MBX's Current ratio of 32.95 is amongst the best of the industry. MBX outperforms 96.88% of its industry peers.
  • MBX has a Quick Ratio of 32.95. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
  • MBX has a Quick ratio of 32.95. This is amongst the best in the industry. MBX outperforms 96.88% of its industry peers.
Industry RankSector Rank
Current Ratio 32.95
Quick Ratio 32.95
MBX Yearly Current Assets VS Current LiabilitesMBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for MBX have decreased strongly by -38.10% in the last year.
EPS 1Y (TTM)-38.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 11.39% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y78.21%
EPS Next 2Y31.87%
EPS Next 3Y18.6%
EPS Next 5Y11.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBX Yearly Revenue VS EstimatesMBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B
MBX Yearly EPS VS EstimatesMBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • MBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBX Price Earnings VS Forward Price EarningsMBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBX Per share dataMBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • MBX's earnings are expected to grow with 18.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.87%
EPS Next 3Y18.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MBX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MBX BIOSCIENCES INC

NASDAQ:MBX (2/25/2026, 11:19:03 AM)

36.55

-0.18 (-0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-17
Inst Owners82.86%
Inst Owner Change-0.94%
Ins Owners2.74%
Ins Owner Change2.29%
Market Cap1.64B
Revenue(TTM)N/A
Net Income(TTM)-80.50M
Analysts82.67
Price Target62.32 (70.51%)
Short Float %5.96%
Short Ratio2.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.26%
Min EPS beat(2)10.09%
Max EPS beat(2)24.42%
EPS beat(4)4
Avg EPS beat(4)15.51%
Min EPS beat(4)8.71%
Max EPS beat(4)24.42%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.98%
PT rev (3m)1.62%
EPS NQ rev (1m)4.02%
EPS NQ rev (3m)13.94%
EPS NY rev (1m)0.96%
EPS NY rev (3m)7.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.23
P/tB 4.23
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-3.02
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS0
BVpS8.63
TBVpS8.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.12%
ROE -20.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.9%
ROA(5y)N/A
ROE(3y)-42.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 499.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.95
Quick Ratio 32.95
Altman-Z 78.62
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)409.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.34%
EPS Next Y78.21%
EPS Next 2Y31.87%
EPS Next 3Y18.6%
EPS Next 5Y11.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.33%
EBIT Next 3Y-30.97%
EBIT Next 5Y-23.38%
FCF growth 1Y-73.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71%
OCF growth 3YN/A
OCF growth 5YN/A

MBX BIOSCIENCES INC / MBX FAQ

What is the ChartMill fundamental rating of MBX BIOSCIENCES INC (MBX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MBX.


What is the valuation status of MBX BIOSCIENCES INC (MBX) stock?

ChartMill assigns a valuation rating of 0 / 10 to MBX BIOSCIENCES INC (MBX). This can be considered as Overvalued.


What is the profitability of MBX stock?

MBX BIOSCIENCES INC (MBX) has a profitability rating of 1 / 10.